Alzheimer Disease and Related DementiasTDCS4MCRNCT06821568
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome
A study testing Personalized Transcranial Direct Current Stimulation (tDCS) in people with Alzheimer Disease and Related Dementias and Cognition, run by Hebrew SeniorLife at 2 sites in 2 countries.
Trial summary
The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in older adults with motoric… Read more about this study
- Who is it for?
- Ages 65 to 90 years
- Conditions the study is for
- Alzheimer Disease and Related Dementias, Cognition, Mobility Disability
- What is being tested?
- Personalized Transcranial Direct Current Stimulation (tDCS)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 128 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 2 Sep 2025to Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 90 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Men and women
- Age 65-90 years
- Subjective cognitive complaints as defined by a 'Yes' response to "Do you feel that you have more problems with memory than most?" or a 'No' response to "is your mind as clear as it used to be?"
- Montreal Cognitive Assessment (MoCA) score ≥21
- Slow gait speed as measured by averaging two 4-Meter walks and defined as a usual walking speed one standard deviation below age and sex-adjusted means.
- Absence of significant disability as defined by the ability to walk over the instrumented gait mat unassisted (e.g., able to walk without any walking aids for at least 2 minutes non-stop) and preserved activities of daily living as defined by a score of less than 9 on the Functional Activities Questionnaire.
Show all 9Show fewer
- Identification of an eligible informant
- Identification of a willing and able tDCS-administrator; i.e., a study partner to lead the administration of home-based transcranial direct current stimulation (tDCS)
- Access to reliable WiFi in the participant's home
Who cannot join
- Formal education less than the 8th grade
- Previous physician diagnosis of dementia
- Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)
- Evidence of moderate-to-severe depressive symptoms defined by a score of ≥9 on the 15-item Geriatric Depression Scale
- History of head trauma resulting in prolonged loss of consciousness
- History of fainting spells of unknown or undetermined etiology that might constitute seizures
Show all 20Show fewer
- History of seizures, diagnosis of epilepsy, or immediate (first-degree relative) family history of epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
- Hospitalization within the past three months due to acute illness, or as the result of a musculoskeletal injury significantly affecting gait or balance
- Any unstable medical condition or chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) or study complication
- Substance use disorders within the past six months
- A hairstyle or headdress that prevents electrode contact with the scalp or would interfere with the stimulation (for example thick braids, hair weave, afro, wig)
- Chronic vertigo
- Myocardial infarction within the past 6 months
- Active cancer for which chemo-/radiation therapy is being received
- Legal blindness
- Visual hallucinations (history or self-report)
- Pacemaker
- Contraindications to MRI or tDCS, including unprovoked seizure within the past two years, risk of ferromagnetic objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), the presence of any active dermatological condition, such as eczema, on the scalp, etc. as outlined by current recommendations for noninvasive brain stimulation endorsed by the International Federation for Clinical Neurophysiology.
- History of REM sleep behavior disorder (RBD), often an early sign of Parkinson's disease
- Medications and medical history will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS active drugs.
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
United States1 site, 1 recruiting
- Recruiting
Hebrew Rehabilitation Center
Roslindale, Massachusetts, 02131
Katie Baldyga, BA, 617-971-5380, Kathrynbaldyga@hsl.harvard.edu
Juhi Salecha, MS, 617-971-5398, JuhiSalecha@hsl.harvard.edu
Israel1 site, 1 recruiting
- Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv
Marina Brozgol, marinab@tlvmc.gov.il
Jeff Hausdorff, PhD
About this study
Official title: Long-term Home-based Transcranial Electrical Stimulation for Cognitive and Motor Function in Older Adults With an Increased Risk of Dementia: a Randomized Controlled Trial
The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in older adults with motoric cognitive risk syndrome (MCR).
Read the detailed description
In older adults, motoric cognitive risk (MCR) is a pre-dementia transition state between "normal" aging and dementia. MCR is associated with impaired function within several brain networks that causes numerous symptoms including loss of memory, the ability to complete complex mental tasks, and the capacity to control one's walking and thus avoid falling and fall-related injuries. This study seeks to assess the short-term and long-term use of an investigational device called a transcranial direct current stimulation (tDCS).
tDCS is a noninvasive technology that enables selective modulation of brain network function, to provide multi-symptom relief to older adults with MCR. By using state-of-the-art technology to 1) utilize a personalized tDCS intervention via an established optimization approach using individual brain MRIs, and 2) complete stimulation in a home-based setting, this study is expected to result in the development of tDCS interventions that have maximal impact on daily life function within this population.
In this study, investigators will conduct a 9-month sham-controlled, double-blinded, multi-site trial in 128 older adults aged 65-90 years old with MCR. All enrolled participants will complete an open-label 2-week, 10-session tDCS intervention. During the open-label phase of the study, all participants will receive active tDCS. Then, participants will be randomly assigned into either the tDCS arm that receives five weekly tDCS sessions for 6 months, or a combination arm of five weekly tDCS sessions for 3 months before or after five weekly sessions of sham for 3 months. Sham treatment is similar to the study tDCS treatment, but omits the key therapeutic element of the treatment being studied. Participants in the combination arm will not know whether they are receiving tDCS or sham during the first or second 3-month period. Enrolled participants will complete assessments relating to cognition, mood, balance, and memory at baseline, after the 2-week open-label phase, after 3 and 6 months of tDCS, and again 3 months later. Once a week, participants will also complete a gait (walking) assessment at home. MRI scans will be performed at baseline, after completing 3 months of tDCS, and after completing 6 months of tDCS.
- Being tested
- Personalized Transcranial Direct Current Stimulation (tDCS), Active-Sham
- Keywords
- Anatomy, Anxiety, Atrophic, Behavioral, Brain, Brain Region, Cephalic, Cognitive, Communities, Dementia, Development, Dose, Double-Blind Method, Electric Stimulation, Enrollment, Evaluation, Exhibits, Exposure to, Frequencies, Future
- Medical subject headings
- Alzheimer Disease, Anxiety Disorders, Atrophy, Behavior, Dementia, Cognition Disorders, Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Personalized Transcranial Direct Current Stimulation (tDCS)Other
Home-based transcranial direct current stimulation (tDCS) tailored to target the left dlPFC.
Active-ShamOther
Stimulation administered in very low-level currents (0.5 mA total) designed to not significantly influence cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
| Study group | Role | What they receive |
|---|---|---|
| Personalized Transcranial Direct Current Stimulation (tDCS) | Experimental | After an initial open-label 2-week home-based transcranial direct current stimulation (tDCS) intervention, participants will receive 5 weekly home-based tDCS sessions for 6 months. Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort. Receives: Other: Personalized Transcranial Direct Current Stimulation (tDCS) |
| Combination Arm; Sham Plus Personalized Transcranial Direct Current Stimulation (tDCS) | Active comparator | After an initial open-label 2-week home-based transcranial direct current stimulation (tDCS) intervention, participants will receive a combination arm of five weekly tDCS sessions for 3 months before or after five weekly sessions of sham for 3 months. The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. Participants in the combination arm will not know whether they are receiving tDCS or sham during the first or second 3-month period. Receives: Other: Personalized Transcranial Direct Current Stimulation (tDCS); Other: Active-Sham |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dual task cost to gait speed
This metric assesses the degree to which performing a secondary cognitive task diminishes the control of gait.
Measured: Pre-randomization baseline; within three days of completing the initial open-label tDCS intervention; Month 3, Month 6; Month 9.
Secondary outcomes (8)
Executive function composite score
This metric is derived from the CANTAB computerized test battery and reflects age-, sex-, and education-based z-scores on numerous cognitive functions associated with executive function.
Measured: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Dual task gait speed
This metric assesses the ability to walk and perform a cognitive task at the same time and predicts cognitive decline and the development of dementia.
Measured: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Preferred gait speed
This metric assesses the preferred gait speed over the course of 4 meters.
Measured: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
The change in left prefrontal deoxygenated hemoglobin between standing and dual task walking
This metric is measured using functional near-infrared spectroscopy (fNIRS) and reflects one aspect of brain activation induced by performing the task of dual task walking and preferred speed.
Measured: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
The change in left prefrontal deoxygenated hemoglobin between standing and usual walking
This metric is measured using functional near-infrared spectroscopy (fNIRS) and reflects one aspect of brain activation induced by performing the task of usual walking and preferred speed.
Measured: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Left dorsolateral prefrontal cortex (dlPFC) gray matter volume
This metric quantifies the volume of gray matter within the left dorsolateral prefrontal cortex (the brain target-of-interest for the tDCS intervention).
Measured: Baseline, Month 3, & Month 6
Left dorsolateral prefrontal cortex (dlPFC) functional connectivity
This metric quantifies the strength of functional connectivity between the left dorsolateral prefrontal cortex (the brain target-of-interest for the tDCS intervention) and the rest of the brain.
Measured: Baseline, Month 3, & Month 6
7-day accelerometry-based physical activity
This metric assesses the quantity and quality of habitual, real-world physical activity.
Measured: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2025
- Study start2 Sep 2025
- Primary completionMar 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer Disease and Related DementiasStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The investigators will conduct a multi-site, sham-controlled, double-blinded, randomized trial of home-based tDCS with stimulation parameters tailored to target the anatomically defined left dlPFC of each participant. Participants will complete baseline cognitive and physical functioning assessments, as well as a structural MRI of the brain. After an initial open-label 2-week tDCS intervention, participants will be randomized into a tDCS arm (5 weekly tDCS sessions for 6 months), or a combination arm of 5 weekly tDCS sessions for 3 months before or after 5 weekly sessions of sham for 3 months via permuted block randomization stratified by sex to ensure that equal number of men and women are randomized to each intervention arm.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hebrew SeniorLife
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA), Tel Aviv Medical Center
- Responsible party
- Principal investigator, Brad Manor, Hebrew SeniorLife
- Investigators
- Brad Manor, PhD, Principal investigator, Hebrew SeniorLifeJeff Hausdorff, PhD, Principal investigator, Tel-Aviv Sourasky Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06821568
- Sponsor's protocol ID
- 00072642
- Other IDs
- 1R01AG081349-01A1
- Acronym
- TDCS4MCR
- Status last verified
- Jul 2026
- First submitted
- 5 Feb 2025
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified demographic, cognitive, motor, clinical, gait kinematics, free-living accelerometry, functional near infrared spectroscopy (fNIRS), MRI, and trial compliance and safety data
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Home-based Transcranial Electrical Stimulation for Cognitive and Motor Function in Older Adults With an Increased Risk of Dementia: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06821568
- Acronym / sponsor ID
- TDCS4MCR / 00072642
- Keywords
- Anatomy, Anxiety, Atrophic, Behavioral, Brain, Brain Region, Cephalic, Cognitive
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- Hebrew SeniorLifeUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA), Tel Aviv Medical Center
- Study start
- 2 Sep 2025 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 12 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in older adults with motoric cognitive risk syndrome (MCR).
Detailed description
In older adults, motoric cognitive risk (MCR) is a pre-dementia transition state between "normal" aging and dementia. MCR is associated with impaired function within several brain networks that causes numerous symptoms including loss of memory, the ability to complete complex mental tasks, and the capacity to control one's walking and thus avoid falling and fall-related injuries. This study seeks to assess the short-term and long-term use of an investigational device called a transcranial direct current stimulation (tDCS).
tDCS is a noninvasive technology that enables selective modulation of brain network function, to provide multi-symptom relief to older adults with MCR. By using state-of-the-art technology to 1) utilize a personalized tDCS intervention via an established optimization approach using individual brain MRIs, and 2) complete stimulation in a home-based setting, this study is expected to result in the development of tDCS interventions that have maximal impact on daily life function within this population.
In this study, investigators will conduct a 9-month sham-controlled, double-blinded, multi-site trial in 128 older adults aged 65-90 years old with MCR. All enrolled participants will complete an open-label 2-week, 10-session tDCS intervention. During the open-label phase of the study, all participants will receive active tDCS. Then, participants will be randomly assigned into either the tDCS arm that receives five weekly tDCS sessions for 6 months, or a combination arm of five weekly tDCS sessions for 3 months before or after five weekly sessions of sham for 3 months. Sham treatment is similar to the study tDCS treatment, but omits the key therapeutic element of the treatment being studied. Participants in the combination arm will not know whether they are receiving tDCS or sham during the first or second 3-month period. Enrolled participants will complete assessments relating to cognition, mood, balance, and memory at baseline, after the 2-week open-label phase, after 3 and 6 months of tDCS, and again 3 months later. Once a week, participants will also complete a gait (walking) assessment at home. MRI scans will be performed at baseline, after completing 3 months of tDCS, and after completing 6 months of tDCS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The investigators will conduct a multi-site, sham-controlled, double-blinded, randomized trial of home-based tDCS with stimulation parameters tailored to target the anatomically defined left dlPFC of each participant. Participants will complete baseline cognitive and physical functioning assessments, as well as a structural MRI of the brain. After an initial open-label 2-week tDCS intervention, participants will be randomized into a tDCS arm (5 weekly tDCS sessions for 6 months), or a combination arm of 5 weekly tDCS sessions for 3 months before or after 5 weekly sessions of sham for 3 months via permuted block randomization stratified by sex to ensure that equal number of men and women are randomized to each intervention arm.
| Arm | Type | Receives |
|---|---|---|
| Personalized Transcranial Direct Current Stimulation (tDCS) | Experimental | Other: Personalized Transcranial Direct Current Stimulation (tDCS)After an initial open-label 2-week home-based transcranial direct current stimulation (tDCS) intervention, participants will receive 5 weekly home-based tDCS sessions for 6 months. Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort. |
| Combination Arm; Sham Plus Personalized Transcranial Direct Current Stimulation (tDCS) | Active comparator | Other: Personalized Transcranial Direct Current Stimulation (tDCS), Other: Active-ShamAfter an initial open-label 2-week home-based transcranial direct current stimulation (tDCS) intervention, participants will receive a combination arm of five weekly tDCS sessions for 3 months before or after five weekly sessions of sham for 3 months. The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. Participants in the combination arm will not know whether they are receiving tDCS or sham during the first or second 3-month period. |
Who may qualify
- Ages
- 65 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (9 listed)
- Men and women
- Age 65-90 years
- Subjective cognitive complaints as defined by a 'Yes' response to "Do you feel that you have more problems with memory than most?" or a 'No' response to "is your mind as clear as it used to be?"
- Montreal Cognitive Assessment (MoCA) score ≥21
- Slow gait speed as measured by averaging two 4-Meter walks and defined as a usual walking speed one standard deviation below age and sex-adjusted means.
Key exclusion criteria (20 listed)
- Formal education less than the 8th grade
- Previous physician diagnosis of dementia
- Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)
- Evidence of moderate-to-severe depressive symptoms defined by a score of ≥9 on the 15-item Geriatric Depression Scale
- History of head trauma resulting in prolonged loss of consciousness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Personalized Transcranial Direct Current Stimulation (tDCS)Home-based transcranial direct current stimulation (tDCS) tailored to target the left dlPFC. | Other | Combination Arm; Sham Plus Personalized Transcranial Direct Current Stimulation (tDCS), Personalized Transcranial Direct Current Stimulation (tDCS) |
| Active-ShamStimulation administered in very low-level currents (0.5 mA total) designed to not significantly influence cortical tissue, but still mimic the cutaneous sensations induced by tDCS. | Other | Combination Arm; Sham Plus Personalized Transcranial Direct Current Stimulation (tDCS) |
Primary outcome
Dual task cost to gait speed
Time frame: Pre-randomization baseline; within three days of completing the initial open-label tDCS intervention; Month 3, Month 6; Month 9.
This metric assesses the degree to which performing a secondary cognitive task diminishes the control of gait.
8 secondary outcomes
Executive function composite score
Time frame: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Dual task gait speed
Time frame: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Preferred gait speed
Time frame: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
The change in left prefrontal deoxygenated hemoglobin between standing and dual task walking
Time frame: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
The change in left prefrontal deoxygenated hemoglobin between standing and usual walking
Time frame: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Left dorsolateral prefrontal cortex (dlPFC) gray matter volume
Time frame: Baseline, Month 3, & Month 6
Left dorsolateral prefrontal cortex (dlPFC) functional connectivity
Time frame: Baseline, Month 3, & Month 6
7-day accelerometry-based physical activity
Time frame: Baseline, within three days of completing initial open-label tDCS intervention, Month 3, Month 6, & Month 9.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: Yes. De-identified demographic, cognitive, motor, clinical, gait kinematics, free-living accelerometry, functional near infrared spectroscopy (fNIRS), MRI, and trial compliance and safety data
Related trials for Alzheimer Disease and Related Dementias
Active, not recruitingPhase 2
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
Alzheimer's Disease
RecruitingPhase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer Disease, Agitation
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Not yet recruiting
Music Listening for Chronic Pain in Adults With Early-Stage Dementia
Chronic Pain, Alzheimer Disease
Not yet recruiting
A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement
Memory Disorders, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Brad Manor, PhD principal investigator
Hebrew SeniorLife
Jeff Hausdorff, PhD principal investigator
Tel-Aviv Sourasky Medical Center
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Personalized Transcranial Direct Current Stimulation (tDCS) in people with Alzheimer Disease and Related Dementias and Cognition, run by Hebrew SeniorLife at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Katie Baldyga, BA (617-971-5380, Kathrynbaldyga@hsl.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dual task cost to gait speed (time frame: Pre-randomization baseline; within three days of completing the initial open-label tDCS intervention; Month 3, Month 6; Month 9.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.